Influenza virus split vaccine

Phase 2Vaccine

SShanghai Institute Of Biological Products

Influenza virus split vaccine is one of 21 biologic programs targeting Influenza. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Avigan

AAppili Therapeutics Inc.

Preclinical

6 4

Influenza virus split vaccine

SShanghai Institute Of Biological Products

Phase 2

3 5

COMIRNATY

Pfizer

Preclinical

1 6

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 7

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 8

Fluvirin

Novartis

Preclinical

3 9

Diphtheria-Tetanus-Acellular Pertussis Vaccine

CanSino Biologics Inc.

Preclinical

1 10

Afluria

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Influenza

NCT07302256

Phase 2Not yet recruiting

Influenza

NCT07327398

Clinical

Trials by Indication[1]

Influenza3 trials

A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months

Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 1·NCT05212623·120 enrolled

Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

Not yet recruiting·SShanghai Institute Of Biological Products·Phase 2·NCT07327398·1,200 enrolled

A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

Recruiting·SShanghai Institute Of Biological Products·Phase 1·NCT07302256·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Influenza virus split vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Influenza virus split vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Influenza virus split vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Institute Of Biological Products company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: SShanghai Institute Of Biological Products

Influenza virus split vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Influenza3 trials

References

Drug Info

Quick Facts

Related News